Induction of apoptosis by chitosan/HPV16 E7 siRNA complexes in cervical cancer cells

Yang,Jun; Li,Shaoping; Guo,Fang; Zhang,Wei; Wang,Yonglian; Pan,Ying

doi:10.3892/mmr.2012.1246

Induction of apoptosis by chitosan/HPV16 E7 siRNA complexes in cervical cancer cells

Authors:
- Jun Yang
- Shaoping Li
- Fang Guo
- Wei Zhang
- Yonglian Wang
- Ying Pan
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xinxiang Medical College, Henan 453100, P.R. China, Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Xinxiang Medical College, Henan 453003, P.R. China
Published online on: December 20, 2012 https://doi.org/10.3892/mmr.2012.1246
Pages: 998-1002

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Consecutive expression of the high‑risk human papillomavirus (HPV) oncoproteins, E6 and E7, is pivotal for malignant transformation and maintenance of the malignant phenotype. These oncogenes may be potential targets of gene silencing‑based molecular therapies for human cervical cancer. The aim of the present study was to evaluate the efficacy of chitosan‑based HPV16 E7 siRNA delivery and the chitosan/HPV16 E7 siRNA complex in the induction of apoptosis in CaSki cells constitutively expressing HPV16 E6 and E7. Chitosan/siRNA nanoparticles were prepared by adding a chitosan solution drop‑wise to an equal volume of siRNA solution. Formation of the chitosan/siRNA complex was verified by gel retardation assays and the entry of siRNA into the cells was confirmed by fluorescence microscopy. Expression of HPV16 E7 was examined by western blot analysis and apoptotic cells were detected by TUNEL staining. Chitosan formed complexes with HPV16 E7 siRNA. The chitosan/siRNA nanoparticles were efficiently delivered into CaSki cells and were observed to induce apoptosis. In conclusion, chitosan is suitable for use as a carrier for delivery of siRNA into cancer cells. The delivery of chitosan/HPV16 E7 siRNA nanoparticles in vivo may serve as a promising therapy for cervical cancer.

View Figures

View References

1	Ma B, Roden R and Wu TC: Current status of human papillomavirus vaccines. J Formos Med Assoc. 109:481–483. 2010. View Article : Google Scholar : PubMed/NCBI
2	Shao J, Chen ZY, Wang J and Ma R: Quantification of human papilloma virus DNA in the plasma of patients with cervical cancer. Clin J Surg Oncol. 2:288–291. 2010.
3	Qiao YL, Zhang WH, Li L, et al: The cross-sectional comparative research of cervical cancer gene screening method. Acta Acad Med Sin. 24:50–53. 2002.
4	Liu X, Roberts J, Dakic A, Zhang Y and Scheleqel R: HPV E7 contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function. Virology. 375:611–623. 2008. View Article : Google Scholar : PubMed/NCBI
5	Chu NR, Wu HB, Wu T, Boux LJ, Sieqel MI and Mizzen LA: Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising mycobacterium bovis bacille calmette-guerin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol. 121:216–225. 2000. View Article : Google Scholar
6	Kaufmann AM, Stern PL, Rankin EM, et al: Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res. 8:3676–3685. 2002.
7	Veldman T, Horikawa I, Barrett JC and Schleqel R: Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J Virol. 75:4467–4472. 2001. View Article : Google Scholar : PubMed/NCBI
8	Nishimura A, Nakahara T, Ueno T, et al: Requirement of E7 oncoprotein for viability of HeLa cells. Microbes Infect. 8:984–993. 2006. View Article : Google Scholar : PubMed/NCBI
9	Dyson N, Howley PM, Münger K and Harlow E: The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 243:934–937. 1989. View Article : Google Scholar : PubMed/NCBI
10	Boyer SN, Wazer DE and Band V: E7: protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 56:4620–4624. 1996.PubMed/NCBI
11	Gonzalez SL, Stremlau M, He X, Basile JR and Münqer K: Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J Virol. 75:7583–7591. 2001. View Article : Google Scholar : PubMed/NCBI
12	Gammoh N, Grm HS, Massimi P and Banks L: Regulation of human papillomavirus type 16 E7 activity through direct protein interaction with the E2 transcriptional activator. J Virol. 80:1787–1797. 2006. View Article : Google Scholar : PubMed/NCBI
13	Zhang B, Chen W and Roman A: The E7 proteins of low- and high-risk human papillomaviruses share the ability to target the pRB family member p130 for degradation. Proc Natl Acad Sci USA. 103:437–442. 2006. View Article : Google Scholar : PubMed/NCBI
14	Caldeira S, Dong W and Tommasino M: Analysis of E7/Rb associations. Methods Mol Med. 119:363–379. 2005.PubMed/NCBI
15	Wu EW, Clemens KE, Heck DV and Münger K: The human papillomavirus E7 oncoprotein and the cellular transcription factor E2F bind to separate sites on the retinoblastoma tumor suppressor protein. J Virol. 67:2402–2407. 1993.
16	Alani RM and Münger K: Human papillomaviruses and associated malignancies. J Clin Oncol. 116:330–337. 1998.
17	Cobrinik D: Pocket proteins and cell cycle control. Oncogene. 24:2796–2809. 2005. View Article : Google Scholar : PubMed/NCBI
18	Dimova DK and Dyson NJ: The E2F transcriptional network: old acquaintances with new faces. Oncogene. 24:2810–2826. 2005. View Article : Google Scholar : PubMed/NCBI
19	Helt AM and Galloway DA: Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J Virol. 75:6737–6747. 2001. View Article : Google Scholar : PubMed/NCBI
20	Wang J, Sampath A, Raychaudhuri P and Baqchi S: Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells. Oncogene. 20:4740–4749. 2001. View Article : Google Scholar : PubMed/NCBI
21	Chen M, Gao S, Dong M, et al: Chitosan/siRNA nanoparticles encapsulated in PLGA nanofibers for siRNA delivery. ACS Nano. 6:4835–4844. 2012. View Article : Google Scholar : PubMed/NCBI
22	Holzerny P, Ajdini B, Heusermann W, Bruno K, Schuleit M, Meinel L and Keller M: Biophysical properties of chitosan/siRNA polyplexes: profiling the polymer/siRNA interactions and bioactivity. J Control Release. 157:297–304. 2012. View Article : Google Scholar : PubMed/NCBI
23	Guo C, Liu K, Zheng Y, Luo H, Chen H and Huang L: Apoptosis induced by an antagonist peptide against HPV16 E7 in vitro and in vivo via restoration of p53. Apoptosis. 16:606–618. 2011. View Article : Google Scholar : PubMed/NCBI
24	Shu XZ and Zhu KJ: The influence of multivalent phosphate structure on the properties of ionically cross-linked chitosan films for controlled drug release. Eur J Pharm Biopharm. 54:235–243. 2002. View Article : Google Scholar : PubMed/NCBI
25	Gref R, Domb A, Quellec P, Blunkc T, Müllerd RH, Verbavatze JM and Langerf R: The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev. 16:215–233. 1995. View Article : Google Scholar : PubMed/NCBI
26	Bivas-Benita M, Romeijn S, Junginger HE and Borchard G: PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium. Eur J Pharm Biopharm. 58:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
27	Panyam J and Labhasetwar V: Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 55:329–347. 2003. View Article : Google Scholar : PubMed/NCBI
28	Zauner W, Farrow NA and Haines AM: In vitro uptake of polystyrene microspheres: effect of particle size, cell line and cell density. J Control Release. 71:39–51. 2001. View Article : Google Scholar : PubMed/NCBI
29	Huang M, Fong CW, Khor E and Lim LY: Transfection efficiency of chitosan vectors: effect of polymer molecular weight and degree of deacetylation. J Control Release. 106:391–406. 2005. View Article : Google Scholar : PubMed/NCBI
30	Chan V, Mao HQ and Leong KW: Effect of chitosan molecular weight in gene delivery process. Abs Pap Am Chem Soc. 221:U347. 2001.
31	Rozema DB and Lewis DL: siRNA delivery technologies for mammalian systems. Targets. 2:253–260. 2003. View Article : Google Scholar
32	Keller M: Lipidic carriers of RNA/DNA oligonucleotides and polynucleotides: what a difference a formulation makes. J Control Release. 103:537–540. 2005. View Article : Google Scholar : PubMed/NCBI
33	Tam P, Monck M, Lee D, et al: Stabilized plasmid-lipid particles for systemic gene therapy. Gene Ther. 7:1867–1874. 2000. View Article : Google Scholar : PubMed/NCBI
34	Bloomfield VA, He S, Li AZ and Arscott PB: Light scattering studies on DNA condensation. Biochem Soc Trans. 19:4961991.PubMed/NCBI
35	Bloomfield VA: Condensation of DNA by multivalent cations: considerations on mechanism. Biopolymers. 31:1471–1481. 1991. View Article : Google Scholar : PubMed/NCBI
36	Bloomfield VA: DNA condensation. Curr Opin Struct Biol. 6:334–341. 1996. View Article : Google Scholar
37	Chang JT, Kuo TF, Chen YJ, et al: Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers. Cancer Gene Ther. 17:827–836. 2010. View Article : Google Scholar : PubMed/NCBI
38	Sima N, Wang W, Kong D, et al: RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53. Apoptosis. 13:273–281. 2008. View Article : Google Scholar : PubMed/NCBI